T
he latest readouts
from eight MMRC
trials across different
stages of disease reported
promising results and
highlighted four new drugs
for multiple myeloma.
For patients with
smoldering myeloma:
A phase II trial reported that highrisk patients with smoldering myeloma
treated with a combination of Empliciti,
Revlimid and dexamethasone showed
benefit in delaying progression
to active multiple myeloma.
For newly diagnosed patients:
A phase II study evaluating extended
treatment of patients undergoing
autologous stem cell transplant with the
combination of Kyprolis, Revlimid and
dexamethasone showed improvements
in disease progression and survival.
ACCEL E RATO R • W I N T E R 2016
For relapsed/refractory
myeloma:
Five early-phase studies evaluated
four new compounds, all showing
promising efficacy in patients that
had previously received many lines of
therapy. These studies underscore the
MMRF’s commitment to ensuring that
patients always have treatment options.
Drugs advanced in MMRC
trials showing promise in
early trials for relapsed/
refractory multiple myeloma:
This has been a truly
exceptional year for
CoMMpass from a
scientific perspective,
and the future is bright
for our patients, with
so many important
insights coming out
of this study.
2 0 1 6
Exciting new data from MMRC
trials presented at ASH
“
A S H
The MMRF had an active presence at the
58th American Society of Hematology
(ASH) Annual Meeting in San Diego, with
27 presentations — 19 resulting from the
CoMMpass Study and 8 resulting from clinical
trials conducted via the Multiple Myeloma
Research Consortium (MMRC) — being reported.
”
—Daniel Auclair, PhD,
Senior Vice President of Research,
MMRF
TOGETHER, THESE FINDINGS
validate the progress of the MMRF’s
Precision Medicine Model and the
importance of patient’s willingness
to donate their tissues to accelerate
research. At the MMRF, collaboration
is a priority. These advances would
not have been possible without the
individuals who enrolled in CoMMpass
and those who funded this effort. These
presentations demonstrate data sharing
in action through CoMMpass, the largest
genomic dataset in oncology — it simply
could not have been accomplished
without data sharing at all levels.
Selinexor, an inhibitor of CRM1, which
works in heavily relapsed patients
Isatuximab, an antibody
against CD-38 like Darzalex
Marizomib, a novel proteasome inhibitor
Venetoclax, an inhibitor of BCL-2, works
best in patients who have t (11;14)
For more information about the
results that were reported at ASH,
go to MMRF’s coverage of the latest
data at themmrf.org/ASH
5